Long Term Treatment With L-DOPS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00889135
Recruitment Status : Approved for marketing
First Posted : April 28, 2009
Last Update Posted : October 18, 2016
Information provided by (Responsible Party):
David Robertson, Vanderbilt University

April 24, 2009
April 28, 2009
October 18, 2016
Long Term Treatment With L-DOPS
This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.
Not Provided
Expanded Access
Drug: droxidopa
Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
Other Names:
  • L-DOPS
  • DOPS
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Approved for marketing
Contact information is only displayed when the study is recruiting subjects
United States
David Robertson, Vanderbilt University
Vanderbilt University
Not Provided
Principal Investigator: David Robertson, M.D. Vanderbilt University Medical Center
Vanderbilt University
October 2016